Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Sarcoma
•
Medical Oncology
What is your preferred second-line therapy for metastatic follicular dendritic cell sarcoma after progression on anthracycline-based chemotherapy?
Sarcoma arose from Castleman disease
Answer from: Medical Oncologist at Academic Institution
Gemcitabine plus a taxane has good reported activity with an RR of 80% - Jain et al., PMID 28382648.
Sign in or Register to read more
20155
Related Questions
Would you offer adjuvant systemic therapy for recurrent fallopian tube leiomyosarcoma after resection of an isolated liver metastasis that presented within 1 year from primary surgery?
How do you approach a young patient with undifferentiated pleomorphic sarcoma of the upper extremity who developed ifosfamide-induced nephrotoxicity after two cycles of adjuvant AIM chemotherapy?
How would you approach patients with primary cardiac sarcomas for adjuvant systemic treatment?
Would you use neoadjuvant TKI or neoadjuvant radiation for a large chest wall sarcoma with an NTRK fusion on NGS?
How do you approach patients with SDH deficient advanced GIST tumor for systemic treatment?
How would you approach adjuvant treatment in a patient with completely resected undifferentiated pleomorphic sarcoma of the chest wall that recurred after 2 years, initially treated with neoadjuvant radiation and resection?
How do you approach a patient with undifferentiated pleomorphic sarcoma encasing the spinal cord post radiation for neurological deficits for further management?
Would you recommend post operative radiation in an adult patient with a thoracic spine osteosarcoma?
How do you approach patients with lymph node positive osteosarcoma of the extremities for neoadjuvant chemotherapy?
What is the recommended approach for a 7 cm x 5 cm paraspinal subcutaneous desmoid tumor (T6 to T9) incidentally detected on PET CT during NSCLC monitoring, with confirmed growth over 18 months?